GEMINI 1 · EFC16033
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A phase 3, randomized, double-blind study evaluating the efficacy and safety of SAR442168 versus teriflunomide (Aubagio®) in patients with relapsing multiple sclerosis (GEMINI 1). EudraCT: 2020-000637-41.
Sponsor: SANOFI
Phase: III
Area: Neuroimmunology